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In 2015 the World Health Organization’s annual World Malaria
Report struck an optimistic note, reporting remarkable progress
against malaria on all fronts since 2000.1 The number of cases
had dropped at speed. Mortality from malaria in Africa, the
most affected continent, had fallen by 61% overall and 71% in
children under 5 years old, with 57 countries reducing their
malaria burden by over 75%. The prospect of eliminating
malaria from some previously endemic areas had improved.
New tools, drugs, and insecticides were being developed and
funding for malaria had increased. This was all the more striking
because during the decades before 2000, antimalarial drug
resistance had risen, as had mortality, particularly among
children in Africa.2
It may therefore surprise people reading the latest report, for
2018, to find a distinctly downbeat tone.3 WHO’s
director-general, Tedros Ghebreyesus, also a distinguished
malariologist, warned that progress against malaria had stalled,
with increases in incident malaria in the highest burden
countries.
As the details of the report make clear, in many areas progress
against malaria continues. WHO estimates there were 435 000
deaths from malaria globally, compared with 451 000 deaths
in 2016, and 607 000 in 2010.3 This is 435 000 deaths too many
for a largely preventable and completely treatable disease, but
it is progress. Outside its heartlands in sub-Saharan Africa,
malaria rates are now mainly low or falling.
The biggest improvement in numerical terms was in India, the
country with the largest burden outside Africa. Malaria incidence
is falling in South East Asia, the historical source of much
antimalarial drug resistance, so important for global control
efforts. China has reported no cases of indigenous malaria for
the first time. Plasmodium vivax malaria globally is declining
faster than many predicted. Some low incidence countries are
closer to elimination. Sub-Saharan Africa contains a few areas
of major progress, mainly in countries with atypical malaria
epidemiology, such as Ethiopia, where incidence of malaria is
still falling.
Unsurprisingly, in countries with substantial natural or human
created disruptions, progress against malaria has reversed:
Venezuela is a good example. In much of Africa—including
most of east Africa and some countries in west Africa, such as
Ghana and Sierra Leone—incidence now seems to be increasing
but mortality is falling. This reflects improved diagnosis and
delivery of services against a background of higher transmission.
Adverse trends
There are, however, serious adverse trends. The most important
is that in several countries, including some with large
populations, such as Nigeria, both number of cases and mortality
are rising, having been on a downward trajectory. WHO is right
to highlight this worrying change.
Several trends are occurring in sub-Saharan Africa, some that
favour malaria and others favouring humans. The two most
obvious biological trends favouring malaria are increasing rates
of mosquito resistance to insecticides, including those used on
bed nets,4 and rising antimalarial drug resistance.5 In an African
context, insecticide resistance will tend to lead to a higher
incidence of disease, while drug resistance is more important
as a risk factor for mortality. It is not yet clear how much of the
increased incidence is attributable to insecticide resistance, but
some is and the pipeline for new insecticides is less well
developed than the pipeline for new drugs.6 7
Any reduction in the push to ensure that children and adults are
protected by insecticide treated bed nets and other antivector
methods will inevitably lead to increasing incidence. WHO data
show some evidence of decreasing enthusiasm among donor
countries for supporting malaria control efforts, and good
evidence now exists that this could erode some of the
extraordinary gains that have been made in the past 18 years.
Although the threat of drug resistance is serious, particularly in
South East Asia,8 in Africa it is probably not (yet) a major reason
for rising malaria incidence. Currently available artemisinin
combination drugs still work across the continent, and even in
regions with rising incidence, most countries have managed to
continue to reduce mortality through treatment.
Long term perspective
Three long term trends are also relevant. The rising proportion
of the population in mosquito unfriendly urban areas and more
high quality housing will work against malaria.9 In the longer
run, the influence of climate change may prove important,
increasing risks in some areas and decreasing them in others.10
An underappreciated trend is that malaria in much of Africa is
moving from a disease that is largely stable and mainly affects
children and pregnant women, to one that will become
epidemiologically unstable, with serious epidemics, including
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in adults who no longer have the immunological protection of
repeated infections.
Outside the malaria heartlands, steady success continues. But
in high incidence countries, particularly in Africa, the
assumption that everything for malaria would steadily continue
to get better should now be abandoned. We are going to have
to use all available tools, appropriately combined, in high
incidence areas and mobilise all the needed resources to give a
sustained push in settings close to durable elimination of malaria.
We have a fight on our hands to regain the momentum of the
first 15 years of the century.
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